GPC3 and cancer: They administered 5 and 10 mg/kg ZnO-NPs daily for 8 weeks and found that the treatment of these animals with these NPs resulted in the inhibition of cancer biomarkers including glypican-3 (GPC3), VEGF, and alpha-fetoprotein (AFP).